Table 5.

Multivariate model analysis for CV events

	Risk ratio (95% CI)	P value
Age in years, vs. 18 to < 30
30 to < 40	1.46 (0.41, 5.24)	0.5596
40 to < 50	4.21 (1.32, 13.41)	0.0150
50 to < 60	8.59 (2.73, 26.97)	0.0002
60 to < 70	10.72 (3.39, 33.96)	< 0.0001
70 to ≤ 75	15.80 (4.62, 54.05)	< 0.0001
Male gender vs. female	2.96 (2.31, 3.78)	< 0.0001
Baseline GI comorbidities	1.25 (0.79, 1.98)	0.3328
Baseline renal comorbidities	0.83 (0.20, 3.40)	0.7945
Baseline CV comorbidities	2.78 (2.07, 3.73)	< 0.0001
Baseline hypertension	1.56 (1.09, 2.23)	0.0156
Baseline diabetes mellitus	1.71 (1.18, 2.48)	0.0049
Duration of treatment in years vs. < 1 year
> 1 to ≤ 3	1.01 (0.79, 1.30)	0.9318
> 3 to ≤ 5	0.80 (0.47, 1.34)	0.3921
> 5	1.77 (0.94, 3.35)	0.0784
Chronic use of NSAIDs (percentage of supply days ≥ 70%) vs . < 70%	1.13 (0.79, 1.60)	0.5004
Mode of administration compared to oral
Patch	1.16 (0.65, 2.09)	0.6145
Other	1.03 (0.69, 1.54)	0.8827
Combination use	0.81 (0.54, 1.22)	0.3166

CI confidence interval, CV cardiovascular, GI gastrointestinal, NSAIDs nonsteroidal anti-inflammatory drugs